NORWALK, Conn.–(BUSINESS WIRE)–The Multiple Myeloma Research Foundation (MMRF) is honored to announce that Kathy Giusti, MMRF Founder and CEO, was presented with an Honorary Doctor of Humane Letters degree from The University of Vermont (UVM) on Sunday, May 19, 2013. UVM celebrated its 211th commencement and presented five outstanding individuals with honorary degrees at the University Commencement Main Ceremony. “I am truly proud to be recognized by my undergraduate alma matter, The University of Vermont,

(More)…

NEW CANAAN, Conn. — New Canaan resident and founder of the Norwalk-based Multiple Myeloma Research Foundation Kathy Giusti received an honorary doctorate from the University of Vermont.  “I am truly proud to be recognized by my undergraduate alma matter, The University of Vermont, with the honorary doctor of humane letters,” Giusti  said in a statement. “My studies at UVM started my path in the scientific field that would ultimately inspire me to develop innovative approaches to speed

(More)…

NEW CANAAN, Conn. — New Canaan resident and founder of the Norwalk-based Multiple Myeloma Research Foundation Kathy Giusti received an honorary doctorate from the University of Vermont.  “I am truly proud to be recognized by my undergraduate alma matter, The University of Vermont, with the honorary doctor of humane letters,” Giusti  said in a statement. “My studies at UVM started my path in the scientific field that would ultimately inspire me to develop innovative approaches to speed

(More)…

New therapies advance the treatment of this hematologic cancer. Multiple myeloma ranks as the second-most prevalent hematologic cancer after non-Hodgkin’s lymphoma and accounts for an estimated 10% of all cancers that affect the blood.1-3 According to the National Cancer Society, an estimated 22,350 adults will be newly diagnosed with multiple myeloma in 2013 and an estimated 10,710 deaths are expected.1,2 Pathology of Multiple Myeloma Multiple myeloma is a malignant neoplasm of plasma cells that accumulates

(More)…

NORWALK, Conn. –  The Multiple Myeloma Research Foundation (MMRF) is honored to announce that Kathy Giusti, MMRF Founder and CEO, was presented with an Honorary Doctor of Humane Letters degree from The University of Vermont (UVM) on Sunday, May 19, 2013. UVM celebrated its 211th commencement and presented five outstanding individuals with honorary degrees at the University Commencement Main Ceremony. “I am truly proud to be recognized by my undergraduate alma matter, The University of

(More)…

Multiple myeloma is a cancerous disease arising from the bone marrow of a patient typically suffering from persistent back pain, fractures, minor trauma or bone pains despite routine treatment. It may also be detected incidentally during a health checkup or if the person is suffering from any particular disease like kidney failure or heart failure. Rarely it causes other soft tissue tumors in the body around the spine or the muscles. At times, a patient

(More)…

Download image BURLINGTON, Mass., May 14, 2013 /PRNewswire/ – Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influences their prescribing decisions for relapsed/refractory multiple myeloma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought leaders are optimistic that the CRd regimen— carfilzomib (Onyx Pharmaceuticals/Ono

(More)…

Surveyed U.S. Payers Demand That New Therapies Provide Significant Efficacy Benefits to Justify Cost, According to a New Report from Decision Resources BURLINGTON, Mass., May 14, 2013 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the factor that most influences their prescribing decisions for relapsed/refractory multiple myeloma, and that increased overall survival

(More)…

New therapies advance the treatment of this hematologic cancer. Multiple myeloma ranks as the second-most prevalent hematologic cancer after non-Hodgkin’s lymphoma and accounts for an estimated 10% of all cancers that affect the blood.1-3 According to the National Cancer Society, an estimated 22,350 adults will be newly diagnosed with multiple myeloma in 2013 and an estimated 10,710 deaths are expected.1,2 Pathology of Multiple Myeloma Multiple myeloma is a malignant neoplasm of plasma cells that accumulates

(More)…

Grammy Nominated Comedian Jim Gaffigan Headlines Comedy Show and Donna Zaccaro Ullman Honored with Spirit of Hope Award NEW YORK–(BUSINESS WIRE)–May 09, 2013– On Tuesday evening over 700 guests from the Tri-State area attended the annual Multiple Myeloma Research Foundation (MMRF) Laugh for Life: New York comedy event at Pier Sixty in New York City. Cat Greenleaf, host of NBC’s Talk Stoop with Cat Greenleaf, served as Master of Ceremonies and Jim Gaffigan, a Grammy

(More)…